Cargando…

Differentiation of atypical pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas: Using whole‐tumor CT texture analysis as quantitative biomarkers

BACKGROUND: To explore the application value of computed tomography (CT) texture analysis in differentiating atypical pancreatic neuroendocrine tumors (pNET) from pancreatic ductal adenocarcinomas (PDAC). MATERIALS AND METHODS: This single‐center retrospective study was approved by local institution...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jiali, Lu, Jingyu, Liang, Ping, Li, Anqin, Hu, Yao, Shen, Yaqi, Hu, Daoyu, Li, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198241/ https://www.ncbi.nlm.nih.gov/pubmed/30151864 http://dx.doi.org/10.1002/cam4.1746

Ejemplares similares

Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels
por: Du, Jiali, et al.
Publicado: (2020)

Pancreatic Collision Tumor of Ductal Adenocarcinoma and Neuroendocrine Tumor
por: Wang, Yuchen, et al.
Publicado: (2018)

Tumor heterogeneity in gastrointestinal stromal tumors of the small bowel: volumetric CT texture analysis as a potential biomarker for risk stratification
por: Feng, Cui, et al.
Publicado: (2018)

The differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma: the values of CT imaging features and texture analysis
por: Guo, Chuangen, et al.
Publicado: (2018)

Prediction of the World Health Organization Grade of rectal neuroendocrine tumors based on CT histogram analysis
por: Liang, Ping, et al.
Publicado: (2020)

CT and MR imaging features of mixed neuroendocrine–non-neuroendocrine neoplasm of the pancreas compared with pancreatic ductal adenocarcinoma and neuroendocrine tumor
por: Zhong, Yanqi, et al.
Publicado: (2023)

A feasible CT feature to differentiate focal‐type autoimmune pancreatitis from pancreatic ductal adenocarcinoma
por: He, Chaobin, et al.
Publicado: (2019)

Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase
por: Reinert, Christian Philipp, et al.
Publicado: (2020)

Serum Metabolite Biomarkers for Pancreatic Tumors: Neuroendocrine and Pancreatic Ductal Adenocarcinomas—A Preliminary Study
por: Skubisz, Karolina, et al.
Publicado: (2023)

Correction to: Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal‑venous enhancement phase
por: Reinert, Christian Philipp, et al.
Publicado: (2021)

Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma
por: Naso, Julia R., et al.
Publicado: (2020)

Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity
por: Schmuck, Rosa B., et al.
Publicado: (2015)

Neutrophil–lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Xiang, Zi-jun, et al.
Publicado: (2020)

Tumor‐driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL‐8
por: Chen, Shao‐jie, et al.
Publicado: (2018)

Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma
por: Li, Tianjiao, et al.
Publicado: (2019)

Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma
por: Rohila, Deepak, et al.
Publicado: (2023)

Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma
por: Lau, Allison N, et al.
Publicado: (2020)

Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma
por: Gao, He-Li, et al.
Publicado: (2020)

Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study
por: Zhou, Huaqiang, et al.
Publicado: (2017)

Assessment of different mathematical models for diffusion‐weighted imaging as quantitative biomarkers for differentiating benign from malignant solid hepatic lesions
por: Hu, Yao, et al.
Publicado: (2018)

Pancreatic Neuroendocrine Tumor with Atypical Radiologic Presentation
por: Singh, Ramandeep, et al.
Publicado: (2015)

Whole-Lesion CT Texture Analysis as a Quantitative Biomarker for the Identification of Homogeneous Renal Tumors
por: Meng, Xiaoyan, et al.
Publicado: (2022)

Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography
por: Ren, Shuai, et al.
Publicado: (2019)

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
por: Zhang, Jingchang, et al.
Publicado: (2022)

Differentiating pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas by the “Duct-Road Sign”: A preliminary magnetic resonance imaging study
por: Xiao, Bo, et al.
Publicado: (2019)

Strong antitumor efficacy of a pancreatic tumor‐targeting oncolytic adenovirus for neuroendocrine tumors
por: Yamamoto, Yuki, et al.
Publicado: (2017)

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
por: Lautizi, Manuela, et al.
Publicado: (2022)

The value of enhanced CT features and texture-signatures in assessing the inflammatory infiltration of pancreatic ductal adenocarcinoma
por: Wang, Fangqing, et al.
Publicado: (2023)

MRI Feature-Based Nomogram Model for Discrimination Between Non-Hypervascular Pancreatic Neuroendocrine Tumors and Pancreatic Ductal Adenocarcinomas
por: Xu, Jiake, et al.
Publicado: (2022)

Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma
por: Croft, Wayne, et al.
Publicado: (2023)

Response to letter to the editor regarding the article “Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase”
por: Reinert, Christian Philipp, et al.
Publicado: (2020)

Exploring the Tumor-Suppressing Potential of PSCA in Pancreatic Ductal Adenocarcinoma
por: Li, Kexin, et al.
Publicado: (2023)

Analysis of distinct long noncoding RNA transcriptional fingerprints in pancreatic ductal adenocarcinoma
por: Yu, Xiang, et al.
Publicado: (2017)

The clinical relevance of the Hippo pathway in pancreatic ductal adenocarcinoma
por: Drexler, Richard, et al.
Publicado: (2020)

Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma
por: Wen, Chenlei, et al.
Publicado: (2020)

Long non-coding RNA in pancreatic adenocarcinoma and pancreatic neuroendocrine tumors
por: Moschovis, Dimitrios, et al.
Publicado: (2017)

Resectable pancreatic ductal adenocarcinoma: association between preoperative CT texture features and metastatic nodal involvement
por: Fang, Wei Huan, et al.
Publicado: (2020)

Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy
por: Smith, Caitlyn, et al.
Publicado: (2022)

Neural Component of the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma
por: Gola, Michał, et al.
Publicado: (2022)

Hepatoid adenocarcinoma in the peritoneal cavity: Two case reports
por: Chen, Xiao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e1jpupu783gerg3b0k0rjoamr8